Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 09 04:00PM ET
36.17
Dollar change
-0.02
Percentage change
-0.04
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y-0.71% Shs Outstand Perf Week-0.86%
SponsorPrincipal Financial Services ETF Type Tagsequity Return% 3Y-12.35% Total Holdings270 Perf Month-1.46%
Fund Family Bond Type Tagshealthcare Return% 5Y2.35% AUM38.77M Perf Quarter-1.91%
Index- Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y27.06%
Index Weighting Commodity Type Tagsbiotechnology Return% SI NAV/sh Perf Year-1.51%
Active/Passive Quant Type Tagsinnovation Flows% 1M-8.06% 52W Range25.66 - 39.75 Perf YTD-0.43%
Dividend TTM- ESG Type Tags- Flows% 3M-18.28% 52W High-9.00% Beta1.00
Dividend Ex-DateDec 29, 2021 Dividend Type Sector/Theme Flows% YTD-20.71% 52W Low40.98% ATR (14)0.62
Expense0.42% Structure Type Region Flows% 1Y RSI (14)52.00 Volatility0.86% 0.94%
Option/ShortNo / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.06 Prev Close36.19
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume5.30K Price36.17
SMA202.64% SMA50-1.31% SMA2007.65% Trades Volume320 Change-0.04%
Jan-26-22 09:38AM
May-12-21 04:45PM
12:00PM
Aug-20-20 05:25PM
Jul-16-20 04:51PM
01:41PM Loading…
Dec-18-19 01:41PM
Dec-02-19 02:40PM
Oct-23-19 10:10AM
Sep-03-19 05:46PM
Jun-24-19 04:23PM
Apr-11-19 03:33PM
Apr-05-19 08:00AM
Apr-02-19 10:00AM
Mar-12-19 11:05AM
Mar-04-19 11:05AM
01:00PM Loading…
Feb-28-19 01:00PM
Feb-27-19 03:00PM
Feb-14-19 10:05AM
Jan-24-19 01:00PM
Mar-01-17 08:59AM
Aug-31-16 09:00AM
Aug-25-16 10:55AM
Aug-23-16 04:04PM
Aug-22-16 04:15PM
12:05PM
Principal Healthcare Innovators ETF seeks long-term growth of capital. Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies in the healthcare sector. It invests significantly in early-stage companies within the healthcare equipment and supplies, pharmaceuticals, biotechnology, and life sciences industries that are not yet consistently profitable.